Results 81 to 90 of about 22,015 (248)

Biases affecting injected doses of an experimental drug during clinical trials. [PDF]

, 2016
During clinical trials, researchers rarely question nominal doses specified on labels of investigational products, overlooking the potential for inaccuracies that may result when calculating pharmacokinetic and pharmacodynamic parameters.
Biollaz, J., Brunner-Ferber, F., Buclin, T., Grouzmann, E., Perrottet, N., Spertini, F., Widmer, N.   +6 more
core   +2 more sources

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, EarlyView.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Ten years of biosimilar recombinant human growth hormone in Europe

Drug Design, Development and Therapy, 2017
Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P
doaj  

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Neurology and Therapy, 2019
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapies.
Judith Steinberg, Yara D. Fragoso, Juan Carlos Duran Quiroz, Juan Raul García, Caroline Guerra, Virginia Rodriguez, Claudia Carcamo Rodriguez, Ethel Ciampi, Edgar Correa-Diaz, Miguel Macías, Nelson Novarro, Darwin Vizcarra, Carlos Oehninger Gatti, Geraldine Orozco, Adriana Carrá   +14 more
doaj   +1 more source

Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]

, 2018
Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen, Carrol, Donal, Courtney, Garry, Mulcahy, Mark, O'Brien, Gary L., Walshe, Valerie   +5 more
core   +1 more source

Biosimilars [PDF]

Zeitschrift für Rheumatologie, 2015
G.-R. Burmester, U. Müller-Ladner
  +8 more sources

Responsible laboratory surveillance of pediatric patients with inflammatory bowel disease on biologic infusion therapy

JPGN Reports, EarlyView.
Abstract The annual healthcare spending on pediatric inflammatory bowel disease (IBD) has increased over time. The objectives of the study were to investigate the cost of routine laboratory surveillance in pediatric IBD patients during outpatient maintenance biologic infusions and determine their impact on clinical management.
Tanmai Shah, Ashwin Agrawal, Héctor E. Alcalá, Anupama Chawla   +3 more
wiley   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources